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Abstract
Introduction and Aims The DIPAK-1 Study investigates
the reno- and hepatoprotective efficacy of the somatostatin
analog lanreotide compared with standard care in patients
with later stage autosomal dominant polycystic kidney
disease (ADPKD). During this trial, we witnessed several
episodes of hepatic cyst infection, all during lanreotide
treatment. We describe these events and provide a review
of the literature.
Methods The DIPAK-1 Study is an ongoing investigator-
driven, randomized, controlled, open-label multicenter
trial. Patients (ADPKD, ages 18–60 years, estimated
glomerular filtration rate 30–60 mL/min/1.73 m2) were
randomized 1:1 to receive lanreotide 120 mg subcuta-
neously every 28 days or standard care during 120 weeks.
Hepatic cyst infection was diagnosed by local physicians.
Results We included 309 ADPKD patients of which seven
(median age 53 years [interquartile range: 48–55], 71%
female, median estimated glomerular filtration rate 42 mL/
min/1.73 m2 [interquartile range: 41–58]) developed eight
episodes of hepatic cyst infection during 342 patient-years
of lanreotide use (0.23 cases per 10 patient-years). These
events were limited to patients receiving lanreotide
(p\ 0.001 vs. standard care). Baseline characteristics were
similar between subjects who did or did not develop a
hepatic cyst infection during lanreotide use, except for a
history of hepatic cyst infection (29 vs. 0.7%, p\ 0.001).
Previous studies with somatostatin analogs reported cyst
infections, but did not identify a causal relationship.
Conclusions These data suggest an increased risk for
hepatic cyst infection during use of somatostatin analogs,
especially in ADPKD patients with a history of hepatic cyst
infection. The main results are still awaited to fully
appreciate the risk–benefit ratio.
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Key Points
Increased risk for hepatic cyst infection during use of
lanreotide has been observed in the ongoing DIPAK-
1 Study.
A literature review also suggested an increased risk
for hepatic cyst infection during use of somatostatin
analogs.
A history of hepatic cyst infection may be a factor
that predisposes for a novel cyst infection.
If a hepatic cyst infection develops, stopping
somatostatin analog treatment should be considered,
based on an assessment of the potential benefit of the
drug vs. the possible increased risk for recurrent cyst
infection.
1 Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is a hereditary progressive disorder characterized by the
formation and growth of renal and hepatic cysts. In most of
the affected patients, progressive renal function loss leads
to end-stage renal disease. In general, there is a need for
renal replacement therapy between the fourth and sixth
decade of life [1]. At the age of 35 years, more than 90% of
ADPKD patients have one or more hepatic cysts [2].
Polycystic liver disease (PLD) is defined as the presence of
C20 hepatic cysts [3]. Hepatic cysts can also occur spo-
radically in the absence of a renal cystic phenotype in
*10% of the population [4]. Patients with PLD in whom
ADPKD is ruled out are referred to as autosomal dominant
polycystic liver disease (ADPLD) [5]. In general hepatic
cysts do not affect liver function [6]. The increase in total
kidney volume (TKV) and total liver volume (TLV) can be
severe and lead to intra-abdominal mass-related com-
plaints, such as abdominal discomfort, pain, and early
satiety, which negatively impact quality of life [7, 8].
Previous small-scale studies suggested that somatostatin
analogs have the potential to slow the rate of kidney
function decline and cyst growth by 50% [9]. The ongoing
DIPAK-1 Study is designed to establish the efficacy of the
somatostatin analog lanreotide, to preserve kidney function
in later stage ADPKD, affecting quality of life and life span
[10]. Known side effects of somatostatin analogs are
transient gastrointestinal complaints, such as diarrhea and
abdominal cramps. There is no evidence suggesting that
these drugs increase the risk for infections [11]. However,
during the DIPAK-1 Study, eight episodes of hepatic cyst
infection developed in seven patients taking lanreotide,
whereas in the control group no such events occurred.
Although hepatic cyst infections have been reported in
several trials that investigated somatostatin analogs
[12, 13], these events have not been causally linked to this
class of drugs.
In this report, we describe the ADPKD patients enrolled
in the DIPAK-1 Study who were diagnosed with a hepatic
cyst infection. We investigate factors that might contribute
to these infections and provide a systematic review of lit-
erature on the occurrence of hepatic cyst infections in other
trials with somatostatin analogs in ADPKD and PLD.
2 Methods
2.1 Study Population and Design
The DIPAK-1 Study is an investigator-driven, randomized,
controlled, open-label, multicenter trial of patients ages
18–60 years with an estimated glomerular filtration rate
(eGFR) of 30–60 mL/min/1.73 m2. Patients were enrolled at
four University Medical Centers in the Netherlands
(Groningen, Leiden, Nijmegen, and Rotterdam) between
June 2012 andMarch 2015. Patients were randomly assigned
in a 1:1 ratio to receive standard care (control group) or
subcutaneous lanreotide injections (120 mg, Somatuline;
Ipsen, Boulogne Billancourt, France), every 28 days for
120 weeks, in addition to standard care (intervention group).
Lanreotide was administered by trained nurses from an
independent home service as part of routine clinical care.
The patient or nurse received the medication from the local
pharmacy. The lanreotide was stored at home until admin-
istration in a refrigerator between 2 and 8 C.
The trial design is described in detail elsewhere (Clini-
calTrials.gov identifier NCT 01616927). The DIPAK-1
Study is conducted in accordance with the International
Conference of Harmonization Good Clinical Practice
Guidelines and the ethical principles that have their origin
in the Declaration of Helsinki. The protocol was approved
by the institutional review board (IRB) of the University
Medical Center Groningen (METc 2012/060), that acted as
the central IRB, and by the IRBs at each trial site. All
patients provided written informed consent.
2.2 Patients with Hepatic Cyst Infection
We performed an interim analysis of the ongoing DIPAK-1
Study using data until 28 January, 2016. At the time of
analysis, all patients were randomized and enrolled for at
least 10 months. Our interim analysis describes the eight
episodes of hepatic cyst infection in seven patients (cases).
This diagnosis was made by the treating physicians based
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on clinical symptoms and additional investigations [14].
These physicians provided detailed information on clinical,
biochemical, microbiological, and imaging results. A body
temperature [38 C was considered as fever. Baseline
characteristics were extracted from the DIPAK-1 Study
database, which allowed a direct comparison between
patients taking lanreotide, with and without hepatic cyst
infection. Specifically, the following patient and disease
characteristics were extracted: demographics, study arm,
body mass index, laboratory results at baseline and, if
applicable, at presentation of cyst infection, DNA mutation
analysis, magnetic resonance imaging (including TLV and
TKV), history of hepatic and/or renal cyst infection, and
history of urinary tract infection. We used center-specific
cutoff-values for laboratory values to identify abnormal
results.
2.3 Literature Review
To investigate the incidence of hepatic cyst infections in
ADPKD and PLD patients in other clinical studies with
somatostatin analogs, we systematically searched the
electronic database of PubMed on 19 January, 2016 using
the following query: [somatostatin AND (ADPKD OR
polycystic kidney disease OR PLD OR polycystic liver
disease)].
2.4 Statistical Analysis
We used descriptive statistics to summarize demographic
and baseline clinical characteristics of patients. Continuous
variables are expressed as mean with standard deviation or
as median with interquartile range, as appropriate. The Chi-
square test and Student t test for parametric data and the
Mann–Whitney U test for non-parametric data were used to
compare baseline characteristics between hepatic cyst
infection cases and the remainder of patients randomized to
lanreotide treatment. All tests were two-tailed and a p value
of\0.05 was considered to indicate statistical significant
differences. Statistical analyses were performed using
SPSS 22 (SPSS Statistics, Inc., Chicago, IL, USA).
3 Results
3.1 Patients with Cyst Infection
Seven of 309 patients (2%) developed a total of eight
hepatic cyst infection episodes. These cases are described
below and clinical details are summarized in Table 1.
Importantly, in all cases the diagnosis of hepatic cyst
infection was made by local physicians, which were not
part of the study team.
3.1.1 Case 1 (Episode 1 and 2)
A 46-year old man with ADPKD and PLD (Fig. 1) pre-
sented with fever (38.7 C) and complained of acute right
upper-quadrant abdominal pain and mild diarrhea
(Table 1). Lanreotide treatment (120 mg) was started
3 months earlier (Fig. 2). At admission, laboratory inves-
tigations showed a grossly elevated serum C-reactive pro-
tein (CRP, 584 mg/L). Urine sediment examination
showed no leukocyturia. Chest radiograph, abdominal
ultrasound, and magnetic resonance imaging were unre-
markable. Local physicians initiated intravenous antibiotic
treatment with three times-daily cefuroxim/metronidazole
plus gentamicin bolus injections. The urine culture was
negative, but blood cultures grew Escherichia coli. Treat-
ment was switched to oral ciprofloxacin and amoxi-
cillin/clavulanic acid. 18Fluorodeoxyglucose positron-
emission computed tomography (18F-FDG PET/CT) was
performed at day 8 after admission to locate the infection
source, which revealed two hepatic cysts showing signs of
infection (Supplementary Fig. 1A). Because of persisting
fever, the hepatic cysts were drained in two sessions at day
9. Cyst aspirations did not cause any complications. Both
cysts contained pus, but cultures remained negative. After
30 days, the patient was discharged and ciprofloxacin
monotherapy was continued for another 4 weeks. Recovery
was uneventful. Lanreotide treatment was continued.
However, 4 months after stopping antibiotic treatment,
this patient again experienced acute abdominal pain in the
right upper quadrant and fever (38.9 C). Laboratory
results showed an increased serum CRP (190 mg/L) and
urinalysis excluded leukocyturia. No liver enzyme data
were available during this second episode. One month after
the diagnosis of the second liver cyst infection episode,
Alkaline phosphatase (ALP) and gamma-glutamyl trans-
ferase (GGT) were increased (respectively, 97 and 144),
aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) were normal. Magnetic resonance imaging
could not locate the source of infection, and urine and
blood cultures were negative. The working diagnosis was
recurrent hepatic cyst infection and local physicians started
intravenous ceftriaxone treatment, which was switched to
oral ciprofloxacin 5 days later. After 6 days, the patient
was discharged, and ciprofloxacin was continued for
another 15 days. Final recovery was without sequelae. One
month after the diagnosis of the second liver cyst infection
episode, ALP and GGT were increased (respectively, 97
and 144), as AST and ALT were normal.
3.1.2 Case 2
A 51-year-old woman with ADPKD and PLD (Fig. 1)
presented at the hospital because of right upper-quadrant
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Fig. 1 Baseline T2-weighted
magnetic resonance imaging of
patients developing hepatic cyst
infection during the DIPAK-1
Study. Height-adjusted liver
volume (hTLV) were 2670,
1579, 823, 2723, 8635, 1901,
and 997 mL/m in respectively,
cases 1–7 (a–f). In five of seven
patients, the phenotype consists
of multiple small- and medium-
sized cysts spread throughout
the liver, with remaining large
areas of non-cystic liver
parenchyma [cases 1–4 (a–d)
and 6 (f)]. One patient [case 5
(e)] showed a phenotype with
massive diffuse involvement of
liver parenchyma by small- and
medium-sized liver cysts, with
only a few areas of remaining
normal liver parenchyma
between cysts. Remarkably, the
liver phenotype of the last
patient who developed a hepatic
cyst infection was limited to a
single hepatic cyst [case 7 (g)]
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abdominal pain, fever (38 C), nausea, and vomiting.
Lanreotide treatment (120 mg) was started 5 months ear-
lier. At admission, serum CRP was 329 mg/L and serum
liver enzymes were normal (AST 29 U/L, ALT 27 U/L,
ALP 57 U/L, and GGT 39 U/L). Local physicians initiated
piperacillin/tazobactam intravenously under the suspicion
of hepatic cyst infection. Blood cultures grew E. coli.
Abdominal CT at admission showed no sign of hepatic cyst
infection. Patient was hospitalized for 3 days. Treatment
was switched to ciprofloxacin twice daily at discharge and
continued for 2 weeks. 18F-FDG PET/CT was performed
3 days after discharge and revealed two hepatic cysts
showing signs of infection. Recovery was uneventful.
3.1.3 Case 3
A 54-year-old woman with ADPKD and PLD (Fig. 1) pre-
sented with fever (39.6 C) and cold shivers without
abdominal pain, after having experienced abdominal com-
plaints during a few weeks following each lanreotide injec-
tion. Lanreotide treatment (120 mg) was started 5 months
earlier. At admission, serum CRP was 245 mg/L and some
liver enzymes were elevated (ALT 62 U/L, ALP 119 U/L,
and GGT 83 U/L). Leukocyturia was excluded with urine
sediment analysis. Abdominal ultrasound showed no
abnormalities, except for gallbladder sludge. Blood cultures
grew E. coli. The patient was hospitalized for 3 days and
treated by local physicians under the suspicion of hepatic
cyst infection with cefuroxime intravenously. At discharge,
treatment was switched to ciprofloxacin for another 11 days.
Recovery was uneventful.
3.1.4 Case 4
A 55-year-old woman with ADPKD and PLD (Fig. 1) and
a history of a hepatic cyst infection (6 months and 1 year
prior to the current event) developed fever (38.9 C) and
right upper-quadrant abdominal pain during a stay abroad.
Lanreotide treatment (120 mg) was started 2 months ear-
lier. She was hospitalized in a foreign country. At admis-
sion, serum CRP and liver enzymes were not determined,
but serum white blood cell count was 9.0 9 10e9/L. Liver
enzymes on day 4 after admission were not raised (AST 17
U/L, ALT 19 U/L, ALP 52 U/L, and GGT 39 U/L). A chest
radiograph and abdominal ultrasound (performed on the
day of admission and 1 day after, respectively) were
unremarkable. A chest radiograph was repeated on the
second day of admission and showed right-sided abnor-
malities compatible with either atelectasis or pneumonia.
In contrast, 18F-FDG PET/CT (performed 3 days after
admission) was unremarkable. All blood cultures were
negative. Under the suspicion of hepatic cyst infection, the
patient was hospitalized for 4 days and treated by local
physicians with intravenous ampicillin-tazobactam, van-
comycin, and meropenem. This was followed by oral
amoxicillin/clavulanic acid for a total of 90 days. Recovery
was uneventful.
3.1.5 Case 5
A 56-year-old woman with ADPKD and PLD (Fig. 1) and
a history of hepatic cyst infection developed right lower-
quadrant abdominal pain and experienced a loss of appe-
tite. The patient had no fever. Lanreotide injections
Fig. 2 Reverse Kaplan–Meier
curve showing time to
development of a first hepatic
cyst infection in autosomal
dominant polycystic kidney
disease patients participating in
the lanreotide and control
groups of the ongoing DIPAK-1
Study (interim analysis). The
median time patients had
received lanreotide until onset
of hepatic cyst infection was
4 months (interquartile range
2–5 months)
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(120 mg) were started 3 months earlier. At admission,
laboratory investigations revealed increased serum CRP
(156 mg/L) and increased serum ALP and GGT (123 U/L
and 106 U/L, respectively). Urine sediment analysis
revealed leukocyturia. Under the diagnosis of hepatic cyst
infection, the patient was treated with cefuroxim/metron-
idazole intravenously for 1 day. Blood and urine cultures
remained negative. 18F-FDG PET/CT (performed 4 days
after admission) showed signs of a hepatic cyst infection
(Supplementary Fig. 1B). Treatment was switched to oral
ciprofloxacin for another 80 days. After 3 days, the patient
was discharged. Recovery was uneventful.
3.1.6 Case 6
A 49-year-old woman with ADPKD and PLD (Fig. 1) was
referred to the hospital because of upper abdominal pain, fever
(38.3 C) with cold shivers and diarrhea. Lanreotide injec-
tions (120 mg) were started 2 months earlier. Because of
complaints of bradycardia and hypotension, the lanreotide
dose was adjusted to 90 mg after the first injection. At
admission, serum CRP was 105 mg/L, with elevated ALP
(150 U/L) and GGT (230 U/L). Urine sediment analysis
revealed leukocyturia. During admission, a chest radiograph
and abdominal ultrasound did not show abnormalities,
whereas amagnetic resonance imaging scan showed an image
of renal cyst hemorrhage in both kidneys. Under the suspicion
of hepatic cyst infection, the patient was treated with oral
ciprofloxacin. Urine and blood cultures remained negative.
Hospitalisation lasted 5 days, and in total ciprofloxacin was
given during 42 days. Recovery was uneventful.
3.1.7 Case 7
A 57-year-old man with ADPKD and a limited number of
hepatic cysts (Fig. 1) was admitted to the hospital because
of fever (39.8 C), right-sided flank pain, diarrhea, vomit-
ing, and headache. Lanreotide injections (120 mg) were
started 19 months earlier. At admission, serum CRP was
elevated (131 mg/L) and liver enzymes were not elevated
(AST 23 U/L, ALT 22 U/L, ALP 71 U/L, GGT 35 U/L).
Leukocyturia was excluded. A chest radiograph and
abdominal ultrasound were unremarkable. Blood cultures
grew E. coli, whereas urine cultures were negative. Under
the suspicion of hepatic cyst infection, the patient was
hospitalized and treatment with ceftriaxone intravenously
was initiated by the local physicians. At discharge, after
3 days, treatment was switched to oral ciprofloxacin for a
total of 7 weeks. Recovery was uneventful.
The time between injection and development of cyst
infection differed widely between patients (1–21 days).
The number of days between injection and cyst infection
for the individual cases was: 16 (case 1 episode 1) 21 (case
1 episode 2), 8 (case 2), 9 (case 3), 8 (case 4), 16 (case 5),
11 (case 6), and 1 (case 7). It was not documented whether
microbiologists were involved in the management of liver
cyst infections and whether antibiotic susceptibilities were
performed.
3.2 Baseline Characteristics of Patients Receiving
Lanreotide
All seven patients that were diagnosed with a hepatic cyst
infection were receiving lanreotide treatment. Baseline
characteristics as listed in Table 2 were not different
between patients randomized to lanreotide or control treat-
ment (data not shown). Therefore, Table 2 provides the
baseline characteristics of only patients treated with lan-
reotide, stratified for cases with (n = 7) and without hepatic
cyst infection during follow-up (n = 147). A history of
hepatic cyst infectionwas present in 29% (n = 2 of 7) of cyst
infection cases, compared with 0.7% (n = 1 of 147) in non-
affected patients (p\ 0.001).Of note, case 1 had two disease
episodes diagnosed as hepatic cyst infection, and the second
episode can therefore be regarded as having occurred in a
patientwith a history of hepatic cyst infection. Following this
line of thinking, a history of hepatic cyst infection was pre-
sent in 43% (n = 3 of 7) of cyst infection cases. At baseline,
sex and age were comparable between cases and non-af-
fected patients (p = 0.32 and p = 0.24, respectively), as
was eGFR, height-adjusted liver volume (hTLV), and
height-adjusted kidney volume (hTKV) (p = 0.97,
p = 0.17, and p = 0.57, respectively). At the time the data
for this report were extracted (28 January, 2016), the total
duration of treatment with lanreotide was 342 patient-years,
indicating an incidence of hepatic cyst infections of 0.23 per
10 patient-years (eight episodes of hepatic cyst infection).
3.3 Literature Review
We identified 13 clinical studies assessing the effect of
somatostatin analogs (lanreotide or octreotide) in ADPKD
or PLD patients between 2005 and 2015 (Table 3). One
study was excluded as this was a post hoc analysis of a
clinical trial that is also included [15]. Of the 12 included
studies [9, 12, 13, 16–24], four studies involved random-
ized placebo-controlled trials [9, 16–18], whereas eight
studies were observational and lacked a control group
[12, 13, 19–24]. A total of 455 patients were included
(ADPKD n = 363; ADPLD n = 92), of whom 375 were
treated with somatostatin analogs. Duration of study
treatment varied between 6 months and 3 years. In seven
trials, intramuscular octreotide-long-acting release (LAR)
40 mg every 28 days was used, and in five trials, subcu-
taneous lanreotide 120 mg was used every 28 days. Total
duration of treatment with somatostatin analogs in these
Hepatic Cyst Infection and Somatostatins
nine studies was 434 patient-years, compared with 151
patient-years with placebo or control treatment.
Four studies (all observational, nonecontrolled)mentioneda
total of six cyst infection cases. All cases occurred in patients
receiving somatostatin analogs [12, 13, 20, 22]. In three
patients, a hepatic cyst infection was diagnosed, [12, 13, 22]
while in the remaining three patients it was not specifically
stated whether a hepatic or renal cyst infection developed
[13, 20]. None of these events were deemed related to study
drug by the authors of the original articles. In the case of all
events being hepatic cyst infection episodes, the incidence rate
would be 0.09 per 10 patient-years during use of somatostatin
analogs. In addition, two studies mentioned two cases with
fever of unknownorigin, bothpatients randomized tooctreotide
treatment [18, 20]. Inonecase, an infectious causewas ruledout
and the patient recovered after discontinuing the study drug,
[20]. whereas the other responded to antibiotic treatment [18].
4 Discussion
In the DIPAK-1 Study, seven patients on the somatostatin
analog lanreotide experienced a hepatic cyst infection,
whereas no hepatic cyst infection was seen in the standard
care group. In other studies with somatostatin analogs,
potentially six hepatic cyst infections were identified,
whereas no such events were observed in patients in the
control or placebo groups.
Hepatic cyst infection is a potential complication of
ADPKD that can be serious, and in nearly all cases leads to
hospitalization [25]. Diagnosing cyst infection represents a
challenge [26]. The cases described in this paper did not
show any prodromi that could be considered as early
symptoms of liver cyst infection. In three of seven cases,
diarrhea was reported but stools were not tested for steat-
orrhea. Diarrhea is a very common side effect of lanreotide
treatment. It has been described in 81% of patients in a
recent trial [13]. In none of the affected cases, stool cul-
tures were performed.
In the case of abdominal pain and increased CRP,
hepatic cyst infection should be included in the differential
diagnosis. The proposed gold standard for diagnosing a
hepatic cyst infection is a cyst aspirate containing white
blood cells and pathogens. However, in clinical care, cyst
aspiration is only rarely performed as a large group of cyst
infections are caused by E. coli and most patients respond
well to antibiotics. Therefore, blood cultures were not
repeated after an episode of cyst infection. Blood and urine
Table 2 Baseline characteristics of patients in the lanreotide group with vs. without hepatic cyst infection
Characteristics Hepatic cyst infection (n = 7) Missing (n) No hepatic cyst infection (n = 147) Missing (n) p value
Female, n (%) 5 (71) 0 77 (52) 0 0.32
Age, years [IQR] 53 [48–55] 0 49 [43–54] 0 0.24
BMI, kg/m2 [IQR] 26 [24–26] 0 26 [24–29] 0 0.19
Serum
Creatinine, lmol/L [IQR] 128 [104–131] 0 130 [109–153] 0 0.51
eGFR, mL/min/1.73 m2 [IQR] 42 [41–58] 0 50 [40–59] 0 0.97
AST, U/L [IQR] 25 [21–29] 0 23 [19–27] 0 0.50
ALT, U/L [IQR] 28 [25–30] 0 23 [18–29] 0 0.12
ALP, U/L [IQR] 66 [49–84] 0 67 [56–80] 3 0.90
GGT, U/L [IQR] 47 [22–105] 0 33 [24–48] 0 0.20
Bilirubin direct, lmol/L [IQR] 5 [3–5] 3 4 [3–5] 37 0.40
Bilirubin indirect, lmol/L [IQR] 6 [1–14] 2 6 [4–8] 30 0.88
Volume
hTLV, mL/m [IQR] 1901 [997–2723] 0 1218 [993–1667] 3 0.17
hTKV, mL/m [IQR] 1093 [529–1893] 0 1150 [798–1658] 4 0.57
TLV[ 2000 mL, n (%) 5 (71) 0 87 (60) 3 0.56
Medical history, n (%)
Hepatic cyst infection 2 (29) 0 1 (0.7) 0 \0.001
Renal cyst infection 1 (14) 0 13 (9) 0 0.63
Urinary tract infection 3 (43) 0 74 (50) 0 0.70
Data are expressed as mean ± standard deviation, percentage, or median with IQR
ALT alanine aminotransferase, ALP alkaline phosphatase, AST aspartate aminotransferase, BMI body mass index, eGFR estimated glomular
filtration rate average baseline and screening, hTLV height-adjusted total liver volume, hTKV height-adjusted total kidney volume, GGT gamma-
glutamyl transferase, IQR interquartile range, TLV total liver volume
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should be cultured when symptoms arise and an 18F-FDG
PET/CT can be of diagnostic help. Antibiotic treatment
should be given for several weeks guided by CRP levels,
though there is no consensus about treatment duration.
Some cases (case 4 and 5) received very long treatment
with antibiotics (90 and 81 days), probably as both patients
had a history of liver infection and the chance for recur-
rence was high. Therefore, physicians sometimes choose to
treat patient for 1–2 months, although this is not evidence
based. First-line treatment with oral ciprofloxacin is rec-
ommended, in the case of failure, percutaneous cyst drai-
nage can be considered.
A systematic review of the literature on hepatic cyst
infections showed that the treatment of hepatic cyst
infection is highly heterogeneous [27]. In the literature,
there is no agreement on how to define ‘treatment success’.
C-reactive protein is a potential biomarker for the evalua-
tion of infection activity; however, in our own clinical
experience, persisting elevated levels of CRP are seen in
the case of hepatic cyst infection [28]. In the eight disease
episodes that are described in this report, all hepatic cyst
infection cases were diagnosed by local physicians as
customary on clinical manifestations, in the absence of a
positive cyst aspirate, but with positive 18F-FDG PET/CT
scans in three patients. In some cases, the Principal
Investigator was involved in the treatment of the liver cyst
infection as the PI has clinical experience treating these
patients. No patient developed tenosynovitis after treatment
with ciprofloxacin.
The exact incidence rate of cyst infections in ADPKD is
unclear. Only one study reported an incidence rate of 8.4%
(33 of 389 patients) renal and/or hepatic cyst infection in
ADPKD patients [25]. The challenge is to differentiate the
clinical picture of hepatic cyst infection with other more
common causes of fever, increased inflammatory markers,
and abdominal pain. Caroli syndrome is characterized by
congenital cystic dilatation of the intrahepatic biliary tree
and therefore not directly comparable with PLD in
ADPKD, in which the liver cysts remain separated from the
biliary tract. As a consequence of dilatation of the biliary
tree, cholangitis is a major problem in these patients [25].
After the fifth report of hepatic cyst infection, the
steering committee and the data safety monitoring board
decided to ask for an interim analysis to assess the risk of
hepatic cyst infection with lanreotide. In retrospect, we
deem the diagnosis of hepatic cyst infection highly likely in
three episodes (case 1 first event, and cases 2 and 5), likely
in three episodes (case 1 s event, and cases 3 and 7), and
possible in two episodes (cases 4 and 6), because in these
latter two cases alternative diagnoses may be considered
(pneumonia and cyst hemorrhage, respectively). In accor-
dance with good clinical practice, however, the diagnosis
as judged by the reporting healthcare professional was
adopted in all cases. We found that baseline liver volume,
kidney volume, age, sex, history of renal cyst infection or
urinary tract infection, and serum liver and kidney
parameters were not different between patients receiving
lanreotide who developed a hepatic cyst infection and those
that did not. This observation is in line with a recent study
of 461 ADPKD patients that failed to detect a relationship
between patient characteristics and infectious complica-
tions [29]. The only difference we found was that lan-
reotide-treated patients who developed a hepatic cyst
infection more often had a history of cyst infection when
compared with lanreotide-treated patients who did not
experience such an event.
A literature search revealed that in other studies inves-
tigating somatostatin analogs in ADPKD and PLD,
including ADPLD, cyst infections occurred in six subjects
receiving active treatment [12, 13, 20, 22]. In three of six
cases, no clear differentiation could be made between
hepatic or renal cyst infections [13, 20]. Even when all
cases were assigned as hepatic cyst infections, the esti-
mated incidence rate in these studies was considerably
lower than in our study (0.09 vs. 0.23 per 10 patient-years).
These small-scale studies did not identify a causal rela-
tionship between cyst infection and use of somatostatin
analogs, but this may be owing to the fact that these studies
included relatively small numbers of patients, often lacked
a control group, and that hepatic cyst infection has a low
incidence.
After evaluation, it was decided that the trial could
continue because all patients who developed a cyst infec-
tion recovered after antibiotic treatment without sequelae,
and because lanreotide might induce a favorable effect on
rate of disease progression. At that moment (6 August,
2013), almost half of the 154 patients who would ulti-
mately receive lanreotide had already entered the DIPAK-1
Study. For safety reasons, however, it was decided to stop
treatment in patients who developed a hepatic cyst infec-
tion, and to add a history of hepatic cyst infection to the
exclusion criteria. Because of this latter exclusion criterion,
lanreotide treatment was withdrawn in one patient. In
addition, the patient’s informed consent form was amended
to provide information on this potential adverse event. The
central IRB agreed with this line of reasoning. Thereafter,
only three additional cases were noted until 28 January,
2016.
From the present data, it is unclear which mechanism
underlies the increased incidence of hepatic cyst infection
during lanreotide use. Liver cysts in ADPKD arise as a
result of ductal plate malformation in the embryonic
development, which leads to large dilated segments of the
primitive bile duct with concomitant abnormal fluid
secretion [6]. It might be possible that bacterial transloca-
tion from the intestinal wall to the liver cysts is involved in
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the occurrence of cyst infections; however, research sup-
porting this theory is lacking [30]. In our cases with a
positive culture, liver infections were caused by E. coli, a
species that is present in the gut in large numbers.
Escherichia coli translocates very efficiently, even across
the histologically intact intestinal epithelium, possibly
owing to a greater ability to adhere to the intestinal mucosa
[31]. Bacterial translocation from the gut to the liver might
be promoted by a reduction in blood flow in the superior
mesenteric artery and portal vein, which is a known effect
of somatostatin analogs [31–33]. Another effect of
somatostatin analogs is a reduction in gallbladder con-
tractility. This leads to reduced bile flow, which might
promote bacterial translocation via the biliary tract.
Another potential mechanism could be that lanreotide
affects the gut immune system by reducing antimicrobial
peptides and proteins located at the epithelium [32].
A potential limitation of the present analysis is that this
is a retrospective interim analysis and that hepatic cyst
infections were not diagnosed centrally but in clinical
centers by local physicians. However, these physicians
were not part of the study team, and were not aware of each
other’s findings, implying that investigator bias is unlikely.
The main strength is that it reports on the largest study with
a somatostatin analog for the indication to slow disease
progression in ADPKD. The large sample size allows a
better estimate of the safety profile of this drug class,
including rare idiosyncratic drug reactions.
In clinical care, somatostatin analogs are used off label
to treat ADPKD and PLD patients’ mass-related com-
plaints as a result of cystic liver disease. The increased
incidence of hepatic cyst infection during use of lanreotide
might be drug related, but may also reflect a class effect, as
suggested by the findings of our systematic literature
search that described incidental cases of hepatic cyst
infection during treatment with other somatostatin analogs.
Based on our experience, we advise physicians to be cau-
tious when prescribing somatostatin analogs to ADPKD
and ADPLD patients with a history of hepatic cyst infec-
tion and that patients should be informed about this
potential risk. In the case of the development of a hepatic
cyst infection, stopping somatostatin analog treatment
should be considered, based on an assessment of the
potential benefit of the drug vs. the possible increased risk
for recurrent cyst infection.
5 Conclusion
During the ongoing DIPAK-1 Study, several cases of
hepatic cyst infection developed in ADPKD patients in the
lanreotide group whereas this was not the case in the
standard care group. A history of hepatic cyst infection
may be a factor that predisposes for a novel cyst infection.
A literature review also suggested an increased risk for
hepatic cyst infection during the use of somatostatin ana-
logs. The main results of the DIPAK-1 Study are still
awaited to fully appreciate the risk–benefit ratio of
somatostatin analogs in ADPKD patients.
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